Reading through the 2020 letters to the SH, $MKL BVPS has compounded close to 10% but stock price has compounded only 3% due to a higher starting p/b and multiple compression.
$MKL — this paragraph below should cause some serious concerns with investors. the insurance business have never done well when they have chased growth before. The underwriting profits or losses always show up years later. Putting a goal on premiums is risky….
$MKL – even though there is a implied combined ratio in the goal. In this industry, it never bodes well to write policies more aggressively especially when one does not know whether it will be a hard or a soft insurance market.
$MKL — with the amount of fixed income that they have to cover for all the insurance losses, one would have hoped that the management would not have had to sell equities during the first half of 2020. Looks like the equity exposure reduced by close to 20%. A significant drag…
$MKL — while Gayner has been rock solid in his investments and it is clear that investing in H1 2020 would have been great only in hindsight, it is also imperative that we call out the reduction in equity exposure during the lows on such a so called conservative balance sheet.
especially since they had raised close to $600M on preferred equity as well in Q2 2020.
Markel has severely under performed the S&P 500 & $BRK in the last 5 years…
2 year and 1 year….
$MKL recently announced their Q1 2021 results. They ended Q1 2021 with BVPS of $913 implying a P/B of 1.33 which is still pretty sporty for $MKL. the good news was that the combined ratio was pretty healthy at 94% and Markel Ventures continues to grow robustly
$MKL has a total SOS of 13.75M which has largely remained the same over the last several years. Continue to hold a significant fixed income portfolio of $787/share & equities portfolio of $547/share. ST investments $198/share and unrestricted cash $282/share
Unpaid losses and unearned premiums which are the main drivers for float are close to $1559/share or close to $21B. Largely unchanged from last year. Net investments gains for the quarter was $526M translating to $38/share
Out of the $43B assets on the balance sheet, $25B are in investments, $7B supporting the insurance operations and $3.7B on Markel Ventures. The ventures portion is still a pretty small portion of the assets from $MKL (a far cry from $BRK.B on that regard)
Markel Ventures net income and EBITDA continues to improve but at a rate lower than revenue growth… The ROA continues to pretty low at this point even from a EBITDA perspective.
Fairly modest buying on equities in Q1 2021 along with fairly thin selling as well. All in all, Gayner is sitting tight. (datasource: Dataroma)
All in all, a solid quarter. No significant changes in the equity portfolio. The valuation is too extremely high but is not too low either. The points in history where it was available close to book value is far and few in between. Ventures is making progress but still a drag!